Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dilanubicel in Single Cord Blood Transplantation for Hematologic Malignancies
NCT03399773Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of dilanubicel in Acute Biphenotypic Leukemia (BAL), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started May 2022; status: active, not recruiting.
02
Drugs
dilanubicel
03
Conditions
Acute Biphenotypic Leukemia (BAL)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03399773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399773.